A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Patritumab Deruxtecan
Related studies linked through entity extraction aliases.
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Status
- RECRUITING
- Phase
- PHASE3
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- Status
- RECRUITING
- Phase
- PHASE2
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion
- Status
- RECRUITING
- Phase
- PHASE2
Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease
- Status
- COMPLETED
- Phase
- PHASE2
A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases
- Status
- WITHDRAWN
- Phase
- PHASE2
NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2